BICYCLE THERAPEUTICS LTD
NASDAQ: BCYC (Bicycle Therapeutics plc)
Last update: 8 hours ago9.30
0.22 (2.42%)
| Previous Close | 9.08 |
| Open | 9.44 |
| Volume | 192,617 |
| Avg. Volume (3M) | 339,637 |
| Market Cap | 644,061,312 |
| Price / Sales | 12.19 |
| Price / Book | 0.640 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -1,824.78% |
| Diluted EPS (TTM) | -2.90 |
| Quarterly Revenue Growth (YOY) | -30.40% |
| Total Debt/Equity (MRQ) | 1.20% |
| Current Ratio (MRQ) | 13.81 |
| Operating Cash Flow (TTM) | -164.72 M |
| Levered Free Cash Flow (TTM) | -104.81 M |
| Return on Assets (TTM) | -16.90% |
| Return on Equity (TTM) | -29.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Bicycle Therapeutics plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
|
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.73% |
| % Held by Institutions | 92.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Dec 2024 | 10,885,357 |
| Point72 Asset Management, L.P. | 31 Dec 2024 | 4,554,900 |
| Fcpm Iii Services B.V. | 31 Dec 2024 | 3,452,330 |
| Westfield Capital Management Co Lp | 31 Dec 2024 | 2,610,337 |
| Armistice Capital, Llc | 31 Dec 2024 | 2,196,000 |
| Siren, L.L.C. | 31 Dec 2024 | 1,839,398 |
| Deep Track Capital, Lp | 31 Dec 2024 | 1,276,081 |
| Tybourne Capital Management (Hk) Ltd | 31 Dec 2024 | 1,269,535 |
| Ra Capital Management, L.P. | 31 Dec 2024 | 1,093,477 |
| Candriam S.C.A. | 31 Dec 2024 | 1,087,876 |
| Ecor1 Capital, Llc | 31 Dec 2024 | 910,000 |
| Principal Financial Group Inc | 31 Mar 2025 | 631,260 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (HC Wainwright & Co., 254.84%) | Buy |
| Median | 24.00 (158.07%) | |
| Low | 14.00 (B. Riley Securities, 50.54%) | Hold |
| Average | 23.17 (149.14%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 9.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 02 May 2025 | 14.00 (50.54%) | Hold | 9.30 |
| JMP Securities | 02 May 2025 | 22.00 (136.56%) | Buy | 9.30 |
| Needham | 02 May 2025 | 29.00 (211.83%) | Buy | 9.30 |
| 09 Apr 2025 | 30.00 (222.58%) | Buy | 6.88 | |
| Barclays | 01 May 2025 | 15.00 (61.29%) | Buy | 9.08 |
| Citizens Capital Markets | 26 Feb 2025 | 26.00 (179.57%) | Buy | 11.32 |
| HC Wainwright & Co. | 26 Feb 2025 | 33.00 (254.84%) | Buy | 11.32 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |